Skip to main content
Year archive

Novartis AG — 2018 filings

All 109 regulatory filings released by Novartis AG (NOVN) in 2018, sourced directly from the official regulator.

109 Filings
2018 Period
2018 filings (109)
Filing Released Lang
FORM 6-K
Foreign Filer Report
2018-12-21 English
Novartis successfully completes acquisition of Endocyte
M&A Activity
2018-12-21 English
FORM 6-K
Foreign Filer Report
2018-12-20 English
Novartis announces new CEO of Oncology Business Unit
Board/Management Information
2018-12-20 English
FORM 6-K
Foreign Filer Report
2018-11-14 English
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
M&A Activity
2018-11-13 English
DFAN14A
Proxy Solicitation & Information Statement
2018-11-06 English
DFAN14A
Proxy Solicitation & Information Statement
2018-11-05 English
DFAN14A
Proxy Solicitation & Information Statement
2018-10-18 English
DFAN14A
Proxy Solicitation & Information Statement
2018-10-18 English
DFAN14A
Proxy Solicitation & Information Statement
2018-10-18 English
DFAN14A
Proxy Solicitation & Information Statement
2018-10-18 English
6-K
Foreign Filer Report
2018-10-18 English
FORM 6-K
Foreign Filer Report
2018-10-18 English
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
Earnings Release Q3 2018
2018-10-18 English
PRIMARY DOCUMENT
Director's Dealing
2018-10-04 English
PRIMARY DOCUMENT
Director's Dealing
2018-09-14 English
FORM 6-K
Foreign Filer Report
2018-09-06 English
FORM 6-K
Foreign Filer Report
2018-08-29 English
FORM 6-K
Foreign Filer Report
2018-08-23 English
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
Regulatory Filings
2018-08-23 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-22 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-22 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-20 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-16 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-14 English
FORM 6-K
Foreign Filer Report
2018-08-14 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-10 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-08 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-06 English
PRIMARY DOCUMENT
Director's Dealing
2018-08-02 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-31 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-27 English
FORM 6-K
Foreign Filer Report
2018-07-27 English
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
Regulatory Filings
2018-07-27 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-25 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-18 English
6-K
Foreign Filer Report
2018-07-18 English
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
Interim / Quarterly Report Q2 2018
2018-07-18 English
PRIMARY DOCUMENT
Director's Dealing
2018-07-13 English
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
Regulatory Filings
2018-06-29 English
FORM 6-K
Foreign Filer Report
2018-06-29 English
FORM 6-K
Foreign Filer Report
2018-06-29 English
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
Capital/Financing Update
2018-06-29 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-19 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-15 English
FORM 6-K
Foreign Filer Report
2018-06-01 English
FORM 6-K
Foreign Filer Report
2018-06-01 English
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
M&A Activity
2018-06-01 English
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
Regulatory Filings
2018-06-01 English
SD
Regulatory Filings
2018-05-31 English
FORM 6-K
Foreign Filer Report
2018-05-18 English
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
Earnings Release Q2 2018
2018-05-18 English
PRIMARY DOCUMENT
Director's Dealing
2018-05-17 English
FORM 6-K
Foreign Filer Report
2018-05-16 English
Novartis announces changes to the Executive Committee
Board/Management Information
2018-05-16 English
3
Director's Dealing
2018-05-15 English
SC TO-T/A Filing
Regulatory Filings
2018-05-15 English
FORM 4
Director's Dealing
2018-05-14 English
FORM 4
Director's Dealing
2018-05-11 English
FORM 4
Director's Dealing
2018-05-09 English
FORM 6-K
Foreign Filer Report
2018-05-03 English
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
Regulatory Filings
2018-05-03 English
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Earnings Release Q2 2018
2018-05-01 English
FORM 6-K
Foreign Filer Report
2018-05-01 English
Novartis provides update on proposed acquisition of AveXis
M&A Activity
2018-05-01 English
SC TO-T/A Filing
Regulatory Filings
2018-05-01 English
4
Director's Dealing
2018-04-23 English
6-K
Foreign Filer Report
2018-04-19 English
FORM 6-K
Foreign Filer Report
2018-04-19 English
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
Board/Management Information
2018-04-19 English
Novartis delivered a strong first quarter and acted to become a more focused medicines company
Earnings Release Q1 2018
2018-04-19 English
3
Director's Dealing
2018-04-18 English
PRIMARY DOCUMENT
Director's Dealing
2018-04-18 English
FORM 6-K
Foreign Filer Report
2018-04-17 English
Novartis tender offer for AveXis commences
M&A Activity
2018-04-17 English
SC TO-T Filing
Regulatory Filings
2018-04-17 English
SC TO-C Filing
Regulatory Filings
2018-04-10 English
FORM 6-K
Foreign Filer Report
2018-04-09 English
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
M&A Activity
2018-04-09 English
SC TO-C Filing
Regulatory Filings
2018-04-09 English
FORM 4 SUBMISSION
Director's Dealing
2018-04-04 English
FORM 3 SUBMISSION
Director's Dealing
2018-03-28 English
FORM 6-K
Foreign Filer Report
2018-03-27 English
Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
M&A Activity
2018-03-27 English
3
Director's Dealing
2018-03-23 English
PRIMARY DOCUMENT
Director's Dealing
2018-03-19 English
FORM 6-K
Foreign Filer Report
2018-03-12 English
NOVARTIS FINANCE S.A. : Directorate change
Board/Management Information
2018-03-12 English
PRIMARY DOCUMENT
Director's Dealing
2018-02-15 English
SC 13G
Major Shareholding Notification
2018-02-14 English
FORM 6-K
Foreign Filer Report
2018-02-09 English
FORM 6-K
Foreign Filer Report
2018-02-01 English
SC 13D
Major Shareholding Notification
2018-02-01 English
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
AGM Information
2018-02-01 English
SC TO-T/A Filing
Regulatory Filings
2018-02-01 English
FORM 6-K
Foreign Filer Report
2018-01-26 English
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Regulatory Filings
2018-01-26 English
IRANNOTICE
Regulatory Filings
2018-01-24 English
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
Report Publication Announcement
2018-01-24 English
20-F
Annual Report FY 2017
2018-01-24 English
6-K
Foreign Filer Report
2018-01-24 English
6-K
Foreign Filer Report
2018-01-24 English
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
Earnings Release Q4 2017
2018-01-24 English
SC TO-T/A Filing
Regulatory Filings
2018-01-22 English
PRIMARY DOCUMENT
Director's Dealing
2018-01-19 English
SC TO-T/A Filing
Regulatory Filings
2018-01-12 English
FORM 6-K
Foreign Filer Report
2018-01-11 English
Novartis appoints Elizabeth Barrett as Oncology Head
Board/Management Information
2018-01-11 English